Variant
EGFR G719
CI-VAR-00001791Explore in graph →ClinVar 16612 CIViC 718 rs28929495
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26773740
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma1 | ||||||||
| EGFR G719 | Erlotinib | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1780In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved p… (full text at CIViC) PMID 26773740 · Klughammer et al., 2016 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma3 | ||||||||
| EGFR G719 | Afatinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11242In this phase 2 study, 129 patients with NSCLC, including those with less common, non-resistant EGFR mutations such as S768I, L861Q, and/or G719X, were treated with afatinib in two cohorts: 99 with a … (full text at CIViC) PMID 22452895 · | |
ClinVar
Clinical significance (1)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
- Source
- NCBI ClinVar (variant_summary)
- Dataset
- ClinVar variant_summary
- Version
- 2026-09-06
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- database
- License
- Public domain (US Government work, NCBI/NLM); acknowledgment requested
- Run
- ING-CLINVAR-20260908-000001
| Variation | Clinical significance | Review status | Stars | Conditions | Origin | Submitters | Last evaluated | Source |
|---|---|---|---|---|---|---|---|---|
| 16612 | Uncertain significance; drug response | criteria provided, multiple submitters, no conflicts | 2 | Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic; Tyrosine kinase inhibitor response; EGFR-related lung cancer; Lung adenocarcinoma; Neoplasm | germline/somatic | 5 | Feb 10, 2025 | clinvar |